These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1906904)

  • 1. Depression of factor XII-dependent fibrinolytic activity characterizes patients with early myocardial reinfarction after recombinant tissue-type plasminogen activator therapy.
    Munkvad S; Jespersen J; Gram J; Kluft C
    J Am Coll Cardiol; 1991 Aug; 18(2):454-8. PubMed ID: 1906904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-lasting depression of the factor XII-dependent fibrinolytic system in patients with myocardial infarction undergoing thrombolytic therapy with recombinant tissue-type plasminogen activator: a randomized placebo-controlled study.
    Munkvad S; Jespersen J; Gram J; Kluft C
    J Am Coll Cardiol; 1991 Mar; 17(4):957-62. PubMed ID: 1900313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variable depletion of endogenous factor XII-dependent fibrinolytic activity following thrombolytic therapy of myocardial infarction and its relation to reinfarction.
    Kluft C; Munkvad S; Gram J; Jespersen J
    Agents Actions Suppl; 1992; 38 ( Pt 2)():299-304. PubMed ID: 1462835
    [No Abstract]   [Full Text] [Related]  

  • 4. Depression of factor XII-dependent fibrinolytic activity in survivors of acute myocardial infarction at risk of reinfarction.
    Pedersen OD; Munkvad S; Gram J; Kluft C; Jespersen J
    Eur Heart J; 1993 Jun; 14(6):785-9. PubMed ID: 8325306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged activation of fibrinolytic system induced by fibrin nonselective thrombolytic agent can contribute to preventing early reocclusion after coronary thrombolytic therapy.
    Goto S; Kawai Y; Handa S; Takahashi E; Ogawa S; Watanabe K; Hori S; Ikeda Y
    Cardiology; 1993; 82(4):274-9. PubMed ID: 8402754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit.
    Voss R; Matthias FR; Borkowski G; Reitz D
    Br J Haematol; 1990 May; 75(1):99-105. PubMed ID: 1695855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.
    Nordt TK; Moser M; Kohler B; Ruef J; Peter K; Kübler W; Bode C
    Thromb Haemost; 1998 Dec; 80(6):881-6. PubMed ID: 9869154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of recurrent ischemia after reperfusion therapy in acute myocardial infarction: a comparison of thrombolytic therapy and primary angioplasty.
    Stone GW; Grines CL; Browne KF; Marco J; Rothbaum D; O'Keefe J; Hartzler GO; Overlie P; Donohue B; Chelliah N
    J Am Coll Cardiol; 1995 Jul; 26(1):66-72. PubMed ID: 7797777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: incidence and effect of smoking.
    Rivers JT; White HD; Cross DB; Williams BF; Norris RM
    J Am Coll Cardiol; 1990 Aug; 16(2):340-8. PubMed ID: 2115538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.
    Collen D; Bounameaux H; De Cock F; Lijnen HR; Verstraete M
    Circulation; 1986 Mar; 73(3):511-7. PubMed ID: 2419009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials.
    Hudson MP; Granger CB; Topol EJ; Pieper KS; Armstrong PW; Barbash GI; Guerci AD; Vahanian A; Califf RM; Ohman EM
    Circulation; 2001 Sep; 104(11):1229-35. PubMed ID: 11551872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non-Q wave myocardial infarction. (LATE Study Investigators).
    Langer A; Goodman SG; Topol EJ; Charlesworth A; Skene AM; Wilcox RG; Armstrong PW
    J Am Coll Cardiol; 1996 May; 27(6):1327-32. PubMed ID: 8626939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
    Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
    J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Variations in hemostasis and fibrinolysis during the treatment of acute myocardial infarct (AMI) with tissue-type plasminogen activator (TTPA). A study of 17 cases].
    Izaguirre Avila R; Ruiz de Chávez Cervantes A; Villavicencio R; Gómez Trigos A; Mar Chavira R; Spíndola Mdel C; Casanova JM
    Arch Inst Cardiol Mex; 1993; 63(3):235-40. PubMed ID: 8347053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeat infusion of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction and early recurrent myocardial ischemia.
    Barbash GI; Hod H; Roth A; Faibel HE; Mandel Y; Miller HI; Rath S; Zahav YH; Rabinowitz B; Seligsohn U
    J Am Coll Cardiol; 1990 Oct; 16(4):779-83. PubMed ID: 2120309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D; Van de Werf F
    Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
    Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
    J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
    Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
    J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.